Chantal Lewis, MD
Endocrinology, Diabetes & Metabolism · Dalton, GANPI 1821439985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 391 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,832, 2.2 times the $825 reported in 2019.
Across 391 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$1K
- Novo Nordisk$909
- Abbott$842
- Medtronic$685
- Lilly USA, LLC$682
- Sanofi-aventis U.S. LLC$655
- plus $4K from 40 others
What the payments were for
- Travel & lodging$2263%
- Food & beverage$7,97894%
- Education$591%
- Other$2303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$226
- Ozempic$217
- ISTURISA$188
- FREESTYLE COPILOT$165
- Omnipod$109
How this compares
$8,494 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 262 | $370,038 |
| OzempicSemaglutide | 294 | $361,684 |
| TrulicityDulaglutide | 122 | $185,073 |
| JardianceEmpagliflozin | 179 | $183,659 |
| Tresiba Flextouch U-200Insulin Degludec | 176 | $179,849 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 83 | $125,612 |
| FarxigaDapagliflozin Propanediol | 118 | $113,318 |
| Humulin R U-500Insulin Regular, Human | 47 | $104,661 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 98 | $88,264 |
| RybelsusSemaglutide | 35 | $63,375 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $62,928 |
| JanuviaSitagliptin Phosphate | 44 | $41,354 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $36,071 |
| Novolog FlexpenInsulin Aspart | 114 | $28,010 |
| Humalog Kwikpen U-100Insulin Lispro | 84 | $27,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $682 | $567,694436 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $909 | $439,162372 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $351 | $242,146253 claims |
| AstraZenecaFarxiga | $41 | $113,318118 claims |
| MerckJanuvia | $92 | $41,35444 claims |
| Sanofi-aventis U.S. LLCLantus | $655 | $5,46212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $66 | $2,105238 claims |
| AbbVieSynthroid | $108 | $1,78723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Dalton
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.